graft contains monocytes which produce several cytokines including G-CSF. 6,7 Randomized studies have demonstrated that r-Hu G-CSF In this placebo-controlled randomized trial we evaluated the hematological and clinical effects of r-Hu GM-(recombinant human granulocyte colony-stimulating factor) or r-Hu GM-CSF (recombinant human granulocyte-macro-CSF after high-dose chemotherapy (HDC) followed by GM-CSF-mobilized PBPC transplantation. Fifty phage colony-stimulating factor) accelerate granulocyte recovery after bone marrow transplantation. [8][9][10][11][12] On the patients with poor prognosis malignancies were randomized in a double-blind study to receive either GMother hand, there are few and controversial reports concerning the efficiency of colony-stimulating factors (CSFs) on CSF or placebo after HDC followed by PBPC rescue. For all patients, PBPCs were recruited using a combithe hematological recovery and on the frequency of infectious complications after PBPC transplantation. [13][14][15][16] [17] [18] At the nation of VP-16 (300 mg/m 2 on days 1 and 2), cytoxan (3 g/m 2 on days 3 and 4) and GM-CSF (5 g/kg from present time, no randomized studies are available regarding the effect of GM-CSF after PBPC transplantation and retroday 5). No differences were demonstrated between the two groups in median time to neutrophil or platelet spective studies are few and not conclusive.
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In this unicenter placebo-controlled randomized trial we recoveries. There was no significant difference between the GM-CSF group and the placebo group in the investigate the effect of r-Hu GM-CSF after GM-CSF-mobilized PBPC transplant. We report neutrophil and platelet median duration of post-transplant hospitalization, in the number of days of antibiotic treatment, in the numrecoveries and related clinical parameters such as the number of febrile days, the rate of infections, the duration of ber of infections and in red blood cell or platelet transfusion requirements. There was a significant difference parenteral antibiotherapy and the time to discharge from hospital after PBPC transplantation. with an advantage for the placebo group in the mean duration of febrile days (P = 0.01). We conclude that the administration of GM-CSF in patients transplanted Patients and methods with GM-CSF-mobilized PBPC is not associated with a clinical benefit in term of tempo of engraftment, numInclusion criteria bers of documented infections, transfusion requirements and mucositis grading.
During the period between January 1993 and September Keywords: rhGM-CSF; placebo; PBPC 1994, 50 patients with poor prognosis malignancies were randomized in a double-blind study to receive either GM-CSF or placebo after HDC followed by GM-CSF-mobilized PBPC rescue. Written informed consent was obtained for Peripheral blood progenitor cell (PBPC) transplantation is all patients. The protocol required approval by the local one approach for restoring hematopoiesis after high-dose ethical committee. chemotherapy (HDC). The main advantage of PBPC trans-A total of 50 patients, 16 with breast cancer, 10 with plants over conventional autologous bone marrow transovarian cancer, eight with non-Hodgkin's lymphoma plants (ABMT) is an accelerated rate of hematopoietic (NHL), four with Hodgkin's disease (HD), five with tesrecovery, particulary of the granulocyte and platelet linticular carcinoma, five with myeloma and two with sarcoma eages. In PBPC transplantation neutrophil and platelet were included in this study. Patient characteristics, listed in recoveries have been reported to be faster than in autolog- Table 1 , are similar between the two groups. At the time ous bone marrow transplantation. [1] [2] [3] The reason for this of HDC all patients (except one NHL) were in complete rapid recovery of hematopoiesis remains unclear but it or partial sensitive tumor response after previous chemopossibly reflects the high number of mature progenitor cells therapy. No patient was excluded from the analysis of this present in the PBPC graft 4,5 and the fact that the PBPC prospective randomized study. with at least 0.5 × 10 9 /l neutrophils for 3 consecutive days.
Mobilizing chemotherapy, leukapheresis
Conditioning regimen (No. of patients) CMA 7 9
Megakaryocyte engraftment was defined as a platelet count Comparisons of hematopoietic recovery after PBPC autografting among GM-CSF and placebo-treated patients were tion (5 g/kg) daily from day 5 and continued until the collection of PBPC was complete.
20 Aphereses were conmade using the Student's t-test (equal variance and normal distribution between the two groups) or the Mann-Whitney ducted during the phase of hematopoietic recovery using a COBE Spectra Cell Separator (Lakewood, CO, USA). After test (unequal variance or abnormal distribution between the two groups). 2 test was used to compare the frequency of collection, cells were cryopreserved and stored in liquid nitrogen.
infections in the two groups. The CFU-GM colony assays and CD34+ cell evaluations were performed as previously described.
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Results
High-dose chemotherapy
Stem cell collection All patients received high-dose chemotherapy depending on With our protocol of PBPC mobilization a total of 51 apherthe diagnosis and followed by transplantation of PBPC.
esis procedures was performed in group 1 and 41 in group The pre-transplant conditioning regimens consisted of:
2. The median number of nucleated cells collected was 2.8 × 10 8 /kg in group 1 and 4.4 × 10 8 /kg in group 2. There (1) cytoxan 120 mg/kg, mitoxantrone 45 mg/m 2 , melwas no significant difference between the two groups. The phalan 140 mg/m 2 (CMA), for breast cancer; (2) carmustine 300 mg/m 2 , VP16 800 mg/m 2 , Ara-C 800 mg/m 2 , melphalan 140 mg/m 2 (BEAM), for non- Table 3 . ber of CD34 + cells was 6.5 × 10 6 /kg in group 1 and Between the two groups no difference was observed in dur-6.8 × 10 6 /kg in group 2. The differences in CFU-GM or ation of hospital stay, in red cells or platelet autonomies, CD34
+ cells between the two groups were not significant. and in number of infections. There was a significant differResults are outlined in Table 2. ence with an advantage for the placebo group in median duration of febrile days Ͼ38°C: 6 days (range 0-21) in group 1 vs 2 days (range 0-23) in group 2 (P = 0.01).
Hematopoietic recovery after PBPC transplant
Therefore there was no difference in median duration of The median time to reach 0.5 × 10 9 /l neutrophils was 12 treatment with parenteral antibiotics: 16 days (range 0-24) days (range 9-84) in the GM-CSF treated patients and 14
in GM-CSF-treated patients compared with 14 days (range days (range 10-23) in the placebo group. Platelet recovery 9-23) in the control group. greater than 20 × 10 9 /l was 13 days (range 7-100) in group There was one death in each group, on day 5 in group 1 and 12 days (range 5-78) in group 2 ( Table 3 ). There 1 (toxic nephropathy), and on day 34 in group 2 (LNH were no statistically significant differences in neutrophil or progressive disease). platelet recoveries between GM-CSF-treated patients and the placebo group. No patients showed graft failure but hematopoietic recovery was delayed in three patients of Discussion group 1 (GM-CSF) and one patient in group 2 (placebo) with a neutrophil recovery Ͼ20 days and platelet recovery PBPC autografting is being used with increasing frequency Ͼ70 days.
as an alternative to ABMT in patients with various malignant disease. When compared to ABMT, the advantages of PBPC transplant include a more rapid restoration for neutrophil and platelet counts, 1-3 a decrease in supportive care 
